NexPlasmaGen Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Later Stage VC
  • (In Progress)

  • Latest Deal Amount
  • $4M

  • Investors
  • 26

NexPlasmaGen General Information

Description

Developer of a cold plasma delivery system designed to reduce cancer recurrence. The company offers a cold plasma device that generates plasma species to produce cellular oxidative stress that kills cancer cells while sparing healthy tissue, enabling hospitals and cancer patients to reduce cancer recurrence and hospital costs and improve patient quality of life.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3801 Wilson Avenue
  • Montreal, Quebec H4A 2T7
  • Canada
+1 (514)
Primary Industry
Therapeutic Devices
Other Industries
Drug Delivery
Biotechnology
Vertical(s)
Corporate Office
  • 3801 Wilson Avenue
  • Montreal, Quebec H4A 2T7
  • Canada
+1 (514)

NexPlasmaGen Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NexPlasmaGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Later Stage VC 11-Jul-2026 $4M In Progress Clinical Trials - Phase 1
13. Later Stage VC 13-Jul-2026 Completed Clinical Trials - Phase 1
12. Later Stage VC 31-Dec-2024 Completed Product Development
11. Angel (individual) 31-Dec-2023 Completed Clinical Trials - Phase 1
10. Accelerator/Incubator 04-May-2023 Completed Clinical Trials - Phase 1
9. Grant 21-Apr-2023 Completed Clinical Trials - Phase 1
8. Grant 31-Jan-2023 Completed Clinical Trials - Phase 1
7. Angel (individual) 30-May-2022 Completed Clinical Trials - Phase 1
6. Grant 01-Jan-2022 $672K $425K Completed Clinical Trials - Phase 1
5. Seed Round 31-Aug-2021 $85K $425K Completed Clinical Trials - Phase 1
To view NexPlasmaGen’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NexPlasmaGen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a cold plasma delivery system designed to reduce cancer recurrence. The company offers a cold plasma device
Therapeutic Devices
Montreal, Canada
2 As of 2026

Takoma Park, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NexPlasmaGen Competitors (1)

One of NexPlasmaGen’s competitors is US Medical Innovations, a Private Equity-Backed company based in Takoma Park, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
US Medical Innovations Private Equity-Backed Takoma Park, MD
You’re viewing 1 of 1 competitors. Get the full list »

NexPlasmaGen Patents

NexPlasmaGen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4824274-A1 Plasma-based treatment of cancer Pending 10-Jun-2024
WO-2025255650-A1 Plasma-based treatment of cancer Pending 10-Jun-2024
CA-3128262-A1 Convertible plasma source and method Active 06-Aug-2019
EP-3906755-A1 Convertible plasma source and method Pending 06-Aug-2019
EP-3906755-A4 Convertible plasma source and method Pending 06-Aug-2019 H05H1/245
To view NexPlasmaGen’s complete patent history, request access »

NexPlasmaGen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NexPlasmaGen Investors (26)

Investor Name Investor Type Holding Investor Since Participating Rounds
9424-7517 Québec Holding Company Minority
Angel (individual) Minority
MSBi Valorisation Venture Capital Minority
SWAN Impact Network Angel Group Minority
Campus des technologies de la santé Accelerator/Incubator
You’re viewing 5 of 26 investors. Get the full list »

NexPlasmaGen FAQs

  • When was NexPlasmaGen founded?

    NexPlasmaGen was founded in 2008.

  • Where is NexPlasmaGen headquartered?

    NexPlasmaGen is headquartered in Montreal, Canada.

  • What is the size of NexPlasmaGen?

    NexPlasmaGen has 2 total employees.

  • What industry is NexPlasmaGen in?

    NexPlasmaGen’s primary industry is Therapeutic Devices.

  • Is NexPlasmaGen a private or public company?

    NexPlasmaGen is a Private company.

  • What is NexPlasmaGen’s current revenue?

    The current revenue for NexPlasmaGen is .

  • How much funding has NexPlasmaGen raised over time?

    NexPlasmaGen has raised $1.03M.

  • Who are NexPlasmaGen’s investors?

    9424-7517 Québec, , MSBi Valorisation, SWAN Impact Network, and Campus des technologies de la santé are 5 of 26 investors who have invested in NexPlasmaGen.

  • Who are NexPlasmaGen’s competitors?

    US Medical Innovations is a competitor of NexPlasmaGen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process